Mr. David Goren, Chief Executive Officer, Chairman of the Board, Director
MBA, Columbia University
David is a seasoned pharma executive with extensive experience in strategy, establishing new life science businesses, and most recently specializing in digital health. David has held various executive commercial and corporate positions in the pharmaceutical industry since 1991. David is currently a strategy consultant to pharma and start-up companies with a focus in life sciences and digital. He also serves as board member of 2 early-stage pharma companies in the oncology and Alzheimer’s therapeutic areas, and provides mentoring and coaching to a variety of executives in healthcare and beyond.
He recently left AstraZeneca (after 10 years) as VP Digital Health Strategy. David established AstraZeneca Israel in 2007, and served as Company President until 2014, when he led the global HR Transformation program. Prior to that, in 2011, David led AstraZeneca’s global initiative to revise the policy for ethical interactions with customers and partners.
In 1997, David created Pfizer’s Israel operation and became the CEO and General Manager of Pfizer Israel. David returned to Pfizer US Headquarters in 2004 to lead the Worldwide Strategy and Business Development Group. Prior to being in Israel, David served in various senior sales and marketing roles.
David has an MBA from Columbia University, a Bachelors in Biology from Clark University, and has attended Harvard, MIT and INSEAD Executive Management Programs.
David has served on various boards including the Raanana Symphonette Orchestra, Kids Kicking Cancer and the Business Ethics Center of Jerusalem.
Dr. Ari S. Kellen, M.D. – Director
Medical Doctor, University of Witwatersrand | MBA, University of Witwatersrand
Dr. Ari Kellen is a seasoned senior executive with over three decades of healthcare industry experience, both in management consulting and in major global P&L operational roles. Dr. Kellen trained and worked as a physician in South Africa while also running a large segment of a 1,000 bed teaching hospital. After being recruited by McKinsey & Company, he spent 23 years serving healthcare clients around the world. Dr. Kellen served for more than a decade as a Senior Partner at McKinsey, advising CEOs and Board members at large industry-leading healthcare companies and small rapidly growing entities. His experience spans biotechnology, medical device, payor and provider organizations, and includes work focused on M&A, business development, new company spin-outs, corporate and business unit level turnarounds, R&D portfolio strategy, and product / therapeutic area growth strategies. In 2014, Dr. Kellen was recruited to Bausch + Lomb / Valeant where he ran a multi-billion dollar P&L across the US and Latin America. As EVP and General Manager of US Bausch + Lomb, he successfully launched and commercialized new products in Pharmaceuticals, Surgical, and Vision Care / Contact Lenses. Dr. Kellen was also responsible for leading the United States R&D organization to advance more than 100 active R&D projects across Dermatology, Ophthalmology, Gastroenterology, Oncology and Consumer Products. Dr. Kellen currently serves on the Advisory Boards of Paragon Biosciences and Castle Creek Pharmaceuticals.
Dr. Shawn Langer, M.D., Director
Medical Doctor, University of Toronto
Dr. Shawn Langer brings over two decades of healthcare industry experience. Dr. Langer was Senior Partner at McKinsey & Company, where he was the leader of its Healthcare Private Equity Group.
During his 15 years with McKinsey & Company, Dr. Langer served healthcare clients across pharmaceuticals, biotechnology, medical devices, and healthcare services.
Most recently Dr. Langer has spent nearly 5 years investing in innovative healthcare companies in his capacity as a portfolio manager at healthcare private equity investment firm BMHS Investments.
Dr. Langer holds an MD from the University of Toronto.
Mordechai Applebaum, PhD MA – R&D Director
Dr. Mordechai Applebaum is an expert in the fields of molecular biology and immunology. Dr. Applebaum completed his doctorate dissertation at The Hebrew University of Jerusalem in the field of embryonic development and molecular biology. Upon completion of his studies he joined Enlivex Therapeutics as a senior scientist and project manager leading the application of the company’s product in novel indications. His activities expanded to include management of preclinical studies, regulatory affairs and business development. He served as VP of content and public relation at JLM-BioCity and a member of the steering committee. Dr. Applebaum also holds an MA in philosophy from The Hebrew University.
Dr. Riva Kovjazin, M.D. – Senior Scientist
M.D., Perm State School of Medicine | Immunology Research Fellow, Rostov Research Institute | Research Fellow, Center for Clinical Immunology, Moscow School of Medicine
Dr. Riva Kovjazin is an expert in the field of immunology with over 25 years of experience in cellular immunology. She obtained her M.D. from the Perm State University School of Medicine, one of the oldest universities in Russia. Dr. Kovjazin then specialized in the advanced study of immunology and epidemiology of conventional infectious diseases at the Rostov Research Institute. In addition, she was a project leader at the Center for clinical immunology, University of Medicine, Moscow, Russia where she studied Clinical immunology and diagnosis aspects of HIV. From 1997 until 2007, Dr. Kovjazin held various positions at XTL Biopharmaceutical
Mr. Gadi Levin, C.A. B.Comm, CFO & Director
Masters of Science (MSc) in Accounting and B.Commerce | Chartered Accountant | MBA
Mr. Levin is an accountant with clinical-stage biotech experience. Mr. Levin served as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes. Mr. Levin served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate. More recently, Mr. Levin served as Chief Financial Officer of BriaCell Therapeutics Corp. developing an immunotherapy for late stage cancer patients.
Mr. Levin began his career at the former “Big Five” accounting firm Arthur Andersen, where he worked in the Cape Town, London, and Tel Aviv offices for nearly ten years. He holds a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a Post-Grad in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.